Le Lézard
Classified in: Health, Science and technology, Business
Subject: VEN

PatientIQ Raises $20M to Transform Patient Outcomes Data into Actionable Intelligence that Advances Clinical Care


Series B Growth Round led by Health Enterprise Partners

CHICAGO, May 12, 2022 /PRNewswire-PRWeb/ -- PatientIQ, a leading healthcare technology company deriving actionable insights from patient outcomes data at scale, announced today it has secured $20 million in Series B funding. The funding round was led by Health Enterprise Partners (HEP), a growth equity firm whose investors include some of the largest health systems and health plans in the United States. August Capital, an early financier of PatientIQ, also participated in this funding round.

PatientIQ partnered with HEP because of its deep industry expertise and long-standing record of scaling healthcare technology businesses. HEP's investment will help advance PatientIQ's mission of driving medicine forward through the systemic collection and analysis of patient outcomes data. Specifically, the company will leverage the investment to further enhance its industry-leading patient outcomes platform and accelerate its expansion in the provider and real-world evidence markets. Following the recent hiring of John Gerhardt as Chief Technology Officer, the company also plans to double in size by the end of 2022 to meet increasing demand for patient outcomes collection and analysis.

"As healthcare continues down the path toward value-based care delivery, the ability to measure and quantitatively define 'quality' is imperative," said Matthew Gitelis, CEO, PatientIQ. "Other industries with far less at stake leverage big data to measure value and improve performance, and HEP's investment will help ensure that healthcare organizations across the country are expertly equipped to optimize clinical outcomes."

"HEP invests in companies that demonstrate an unmatched commitment to achieving clinical and operational excellence," said Dave Tamburri, Managing Partner, HEP. "The PatientIQ platform is a best-in-class product that will inspire the collaboration and innovation needed to advance clinical practice. We are thrilled to partner with Matthew Gitelis, Michael Casey, and the entire PatientIQ team to accelerate the company's growth." Tamburri will serve on the PatientIQ Board of Directors.

The $20 million Series B raise follows a tremendous period of growth for PatientIQ. In just two years, the company has matured its customer base from 29 healthcare organizations to more than 200, collecting outcomes data from more than 1.4 million patients. The volume of outcomes collected has also grown substantially to almost 6 million, which provides clinicians and researchers with a robust database they can leverage to benchmark performance, predict patient outcomes, and collaborate to enable better care.

About PatientIQ
PatientIQ is the healthcare technology partner for deriving actionable insights from patient outcomes data. The PatientIQ platform is a cloud-based solution that empowers hospitals, health systems, private practices, and industry partners to systemically collect, measure and analyze patient-reported outcomes data to improve clinical and operational performance. With the single, EHR-integrated platform, leveraging a proprietary analytics engine, healthcare organizations are empowered to continuously capture patient progress and derive intelligent insights that enable better care - without increased administrative burden. In addition to outcomes analysis, the platform facilitates collaboration, bringing together data-driven clinicians from across the country to accelerate research, participate in registries, and push medicine forward. PatientIQ has demonstrated years of experience and a superior ability to transform patient outcomes into actionable intelligence. For more, visit http://www.patientiq.io.

About Health Enterprise Partners
Health Enterprise Partners invests in innovative healthcare services and technology companies that deploy solutions that matter. Central to HEP's strategy is its unique and extensive hospital system and health plan network, 36 members of which are investors in HEP's funds. HEP seeks to invest in companies that improve the quality of the patient experience, expand access, and reduce the cost of healthcare. https://hepfund.com/

About August Capital
August Capital is an early-stage venture capital fund located in the San Francisco Bay Area, with multiple fund vintages since our founding in 1995. We currently manage approximately $2 Billion in aggregate capital commitments. Over the last 25+ years, we have invested in breakthrough startups across the technology sector such as Atheros, Seagate, Ebates, Splunk, Zulily, Fastly, Bill.com, and GitLab. We have a team of investment professionals that are open-minded, creative, flexible, experienced, and well-networked. We believe in serving as a resource to support and guide entrepreneurial teams as they pursue their company vision

Media Contact

Kendall Shadley, PatientIQ, 1 231-557-2906, [email protected]

 

SOURCE PatientIQ


These press releases may also interest you

at 19:40
ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced its ongoing commitment to exploring the therapeutic opportunity of glycobiology through support for ongoing research at GanNA Bio, and the...

at 19:05
Appili Therapeutics Inc. (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced it has secured additional bridge financing in the amount of C$300,000...

at 19:00
David J. Dykeman, co-chair of the Life Sciences & Medical...

at 18:30
Aspire Health Alliance ("Aspire Health") is a company headquartered in Braintree, Massachusetts, that provides behavioral health services in the community.  Aspire Health experienced a data security incident that may have involved personal and...

at 17:21
Chemistree Technology Inc. (US OTC: CHMJF) (the "Company" or "Chemistree"), is pleased to announce that the adjourned extraordinary meeting of the holders of the 10% senior unsecured convertible debentures of the Company (the "Debentures") was...

at 17:15
Summary Product: Counterfeit Viagra, 100 mg sildenafil tabletsIssue: Health products - Product safety, Unauthorized productWhat to do: Immediately stop using and safely dispose of this product. Consult your health care provider if you have taken this...



News published on and distributed by: